Form 6-K SINOVAC BIOTECH LTD For: May 08

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

 

Commission File Number: 001-32371

 

 

SINOVAC BIOTECH LTD.

 

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒        Form 40-F ☐

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	SINOVAC BIOTECH LTD.
	By:	/s/ Nan Wang
	Name:	Nan Wang
	Title:	Chief Financial Officer

 

Date: May 8, 2026

 

 

Exhibit Index

 

Exhibit 99.1

Press Release - SINOVAC Reports Unaudited First Half of 2025 Financial Results

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE - SINOVAC REPORTS UNAUDITED FIRST HALF OF 2025 FINANCIAL RESULTS

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
• Ambulatory Surgical Centres Poised for Sustained Growth as Healthcare Delivery Continues to Shift Beyond the Hospital
• Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Embecta Corp. (NASDAQ: EMBC); Navan, Inc. (NASDAQ: NAVN); and Power Solutions International, I